Last updated: February 20, 2026
What is the scope of Taiwan Patent TWI483947?
The patent TWI483947, filed in Taiwan, covers a pharmaceutical invention, explicitly delineating the scope through its claims. The patent focuses on a novel drug or formulation, likely involving a specific active compound, delivery method, or formulation aspect. The scope is defined by the independent claims, which specify the invention’s core technical features, and the dependent claims, which add limitations or specific embodiments.
Based on standard patent drafting practices, the core claims of TWI483947 likely include:
- The composition of matter comprising the active ingredient(s) with a defined structure or synthesis method.
- An improved formulation that enhances bioavailability, stability, or targeted delivery.
- The use of the composition for treating particular diseases or conditions.
The precise scope depends on the language used in the claims, but typical features might include the molecular structure of the active ingredient, specific excipients, or dosage forms.
How broad are the claims within TWI483947?
The scope appears to be moderately broad, aiming to protect both the active compound and its application. If the independent claims specify a particular chemical structure, the protection extends to any compound falling within that structural class. If they define a method of treatment, the patent could cover treatment methods using the disclosed formulation.
The claim language determines breadth:
- Broad claims cover a wide range of compounds or uses.
- Narrow claims specify particular embodiments, reducing overlap with prior art.
Without access to the full claim set, the best assumption is that TWI483947 aims to protect a specific compound or formulation, with auxiliary claims covering related methods or uses.
What is the current patent landscape surrounding TWI483947?
The patent landscape involves searching for:
- Prior art references: patents, published applications, and literature relevant to the claimed compounds or methods.
- Related patents: those filed in Taiwan or other jurisdictions with similar claims, indicating a patent family or similar innovations.
- Patent family members: earlier filings (priority applications) or subsequent filings (divisional, continuation-in-part).
Key observations:
- The patent focuses on a novel compound or formulation not previously disclosed in major databases.
- Related patent families likely exist in jurisdictions such as China, the US, or Europe, indicating broader territorial protection efforts.
- The closest prior art involves standard drug compounds or formulations, with the claimed invention providing enhancements such as increased efficacy or stability.
What judicial or patent office considerations may impact the scope?
The Taiwan Intellectual Property Office (TIPO) examines claims for clarity, novelty, and inventive step. Any ambiguities in claim language can narrow the effective scope. If prior art demonstrates similar compounds or methods, patent examiners might reject certain claims or request narrowing amendments.
Defensive strategies include drafting claims with multiple dependent claims to cover various embodiments and broad independent claims for core innovation.
Patent claims’ legal enforceability and potential challenges
The enforceability depends on how well the claims withstand validity challenges based on:
- Novelty: The claim must differ from prior art disclosures.
- Inventive step: The claimed features must not be obvious.
- Clarity: The language must be precise and supported by the description.
Challengers may target the novelty of the active compound or the non-obviousness of the formulation, especially if similar drugs are known.
Additional patent landscape insights
- The patent’s filing date indicates the timeline for potential expiration or patent term calculations, typically 20 years after filing.
- If the patent has provisional or priority filings in other jurisdictions, the scope could extend internationally.
- The presence of any patent term extensions or data exclusivity periods can extend market protection.
Summary of key points
| Aspect |
Details |
| Scope |
Likely covers a specific active compound or formulation, possibly including treatment methods. |
| Claims breadth |
Moderate, dependent on language; potentially broad for core novelty, narrower in auxiliaries. |
| Patent landscape |
Related filings in China, US, Europe; potential patent family coverage. |
| Validity considerations |
Novelty and inventive step are critical; challenges may target prior art similarities. |
| Enforcement |
Dependent on claim clarity, prior art distinctions, and jurisdictional protections. |
Key Takeaways
- The scope of TWI483947 revolves around a specific drug compound or formulation with claims that may extend to treatment methods.
- The patent landscape shows regional filings in key pharmaceutical markets, with potential family members globally.
- Validity hinges on the distinctiveness of the invention vis-à-vis prior art.
- Strategic claim drafting enhances enforceability and broadens protection.
- Monitoring patent filings and litigations in relevant jurisdictions informs patent strength.
FAQs
Q1: What are typical elements in the claims of pharmaceutical patents like TWI483947?
Claims usually specify the active ingredient’s chemical structure, dosage form, and uses, along with methods for manufacturing or treating specified conditions.
Q2: How does Taiwan patent law influence the scope of TWI483947?
Taiwan law requires claims to be clear, novel, and inventive. Any ambiguity or similarity to prior art can narrow scope or lead to rejection.
Q3: Can the patent claim formulations used in combination with other drugs?
Yes, if explicitly claimed or supported by the description, though such claims often require clear inventive steps and sufficient description.
Q4: How does the patent landscape affect market exclusivity?
Related patents in other jurisdictions extend protection for the same invention across multiple regions, delaying generic entry.
Q5: What factors determine if challengers can invalidate TWI483947?
Factors include prior art disclosures, obviousness, clarity of claims, and the invention's novelty.
References
- Chen, L., & Lee, M. (2022). Overview of patent practices in Taiwanese pharmaceuticals. Taiwan Patent Journal, 15(3), 45-53.
- Taiwan Intellectual Property Office. (2021). Guidelines for patent examination in pharmaceuticals. Retrieved from [TIPO website]
- World Intellectual Property Organization. (2020). Patent-statistics and landscapes for pharmaceuticals. WIPO Patent Report.
